Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy

Trial Title: Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy

NCT ID: NCT06006806

Condition: Breast Cancer
Breast Cancer Stage II
Breast Cancer Stage III
Breast Cancer Stage I

Conditions: Official terms:
Breast Neoplasms

Study type: Interventional

Study phase: N/A

Overall status: Recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Intervention model description: The goal of this study is to measure skin reactions during proton therapy for 100 patients over a period of three years.

Primary purpose: Supportive Care

Masking: None (Open Label)

Intervention:

Intervention type: Radiation
Intervention name: Pencil Beam Scanning Proton Therapy
Description: Part of the normal proton therapy process is to have a CT scan (called a CT simulation) performed that is used to create a proton treatment plan. A proton treatment plan is a computer model of the proton beam that is used to calculate where the protons will go inside the body. During the treatment planning process, the clinical team works to find the best possible placement of the protons. This study uses a process called "Spot Delete" to keep protons from stopping in the skin, which is believed to be related to skin reddening. Spot Delete is a software application that was developed at the Thompson Proton Center and is used in the treatment planning process.

Other name: Spot Delete

Summary: This purpose of this study is to examine skin reactions (called radiation dermatitis) that occur during pencil beam scanning (PBS) proton therapy. The researchers will test a unique technique called "Spot Delete" to see if it can reduce skin reactions for breast patients treated with PBS. They will also use a special computer model to study how the energy of the proton beam (linear energy transfer) is related to these skin reactions. The study involves creating a treatment plan based on a CT scan, which helps guide the proton beam in the body. The clinical team uses this CT scan to find the best placement for the protons. The "Spot Delete" method prevents protons from stopping in the skin, which is thought to cause skin redness.

Detailed description: During the study, digital photos of patients' skin will be taken to assess the amount of redness, without revealing their identity. Patients will be given a self-report questionnaire and medical staff will document the skin reactions in the patients' medical charts. The degree of skin reactions will be compared against historical occurrence rates, and the location of any skin reactions that occur will be compared against the predicted location from the computer model. In this study, we aim to test the hypothesis that the "Spot Delete" technique in proton therapy reduces radiation dermatitis in breast cancer patients compared to historical data from patients who underwent regular proton therapy without the technique. To evaluate this, we will compare the extent of skin reactions in patients who receive proton therapy with the "Spot Delete" technique to historical data from patients who did not receive this treatment. The effectiveness of the technique will be evaluated by measuring and documenting the degree of skin reactions in patients undergoing proton therapy with the Spot Delete technique. Digital photographs of the treatment area will be taken to assess radiation dermatitis using the treatment using the Common Terminology Criteria for Adverse Events (CTCAE) ver. 5.0 and using the Radiation Dermatitis Severity (RDS) scoring system. Radiation dermatitis will be assessed at baseline, weekly after every fifth treatment session, at the end of treatment, and at 2 post treatment follow-up appointments (e.g. 1-month and 6-months post treatment).These results will be compared to historical occurrence rates of skin reactions in regular proton therapy.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - The patient must consent to be in the study and must have signed an approved consent form conforming to federal and institutional guidelines. - Patients must be equal to or greater than 18 years old. - The patient must have stage 0, I, II, or III breast cancer - On histological examination, the tumor must be ductal carcinoma in-situ (DCIS) or invasive adenocarcinoma of the breast - Surgical treatment of the breast must have been lumpectomy or mastectomy - Patients must have an estrogen receptor (ER) analysis performed on the primary tumor - Progesterone (PgR) analysis is desired but not mandatory - No serious health conditions as determined by physician that would impact ability to complete treatment or impact skin in the area of treatment Exclusion Criteria: - Stage IV breast cancer - Non-epithelial breast malignancies such as sarcoma or lymphoma - Paget's disease of the nipple - Prior breast or thoracic radiation therapy (RT) for any condition. - Collagen vascular disease, specifically dermatomyositis with a Creatine phosphokinase (CPK) level above normal or with an active skin rash, systemic lupus erythematosis, or scleroderma. - Pregnancy or lactation - Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements.

Gender: Female

Gender based: Yes

Gender description: Men are not eligible for this study

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Thompson Proton Center

Address:
City: Knoxville
Zip: 37909
Country: United States

Status: Recruiting

Contact:
Last name: Casey Mastio-Partridge, BS, MLS

Phone: 865-331-8216
Email: cmastio@covhlth.com

Contact backup:
Last name: Jessica M Severt, RN, BSN

Phone: 865-331-4966
Email: jsevert@covhlth.com

Investigator:
Last name: Ryan Grover, MD
Email: Sub-Investigator

Investigator:
Last name: Brion Shin, MD
Email: Sub-Investigator

Investigator:
Last name: Allen Meek, MD
Email: Sub-Investigator

Investigator:
Last name: Chester Ramsey, Ph.D
Email: Sub-Investigator

Investigator:
Last name: Samantha Hedrick, Ph.D
Email: Principal Investigator

Start date: July 7, 2023

Completion date: July 7, 2027

Lead sponsor:
Agency: Thompson Cancer Survival Center
Agency class: Other

Source: Thompson Cancer Survival Center

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06006806